SCHEDULE: AN2 Therapeutics: Eric Easom Discloses 6.2% Stake

Eric Easom, CEO of AN2 Therapeutics, Inc., has filed a Schedule 13G, disclosing beneficial ownership of 2,409,486 shares, representing 6.2% of the company's common stock.

Summary

• Eric Easom, CEO of AN2 Therapeutics, Inc., has filed an amended Schedule 13G, reporting beneficial ownership of 2,409,486 shares of common stock.
• This holding represents 6.2% of the company's outstanding common stock.
• The shares are held directly, through family trusts where Mr. Easom is trustee, and through vested or soon-to-vest stock options.
• The filing is based on the number of outstanding shares as of August 6, 2026, as reported in the company's Form 10-Q filed on August 11, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily reflecting routine ownership disclosure rather than significant company performance changes.

Positives

• The CEO's significant beneficial ownership indicates alignment with shareholder interests.
• The disclosure of vested or soon-to-vest stock options suggests potential future equity participation and incentive alignment.

Negatives

• The filing does not contain any new financial performance data or strategic updates that would indicate a change in the company's operational status.

Risks

• The filing does not explicitly mention any new risks. However, general risks associated with stock ownership, such as market volatility and company performance, are implicitly present.

Future Outlook

This filing is primarily an ownership disclosure and does not contain forward-looking statements or specific future guidance from the company.

Management Comments

• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for significant shareholders, including company insiders, and are routine disclosures required by the SEC to inform the market about ownership stakes.

Stakeholder Impact

• Shareholders are informed about the CEO's substantial and vested stake, which can be viewed as a positive indicator of management commitment.

Key Dates

Keywords

AN2 Therapeutics, Schedule 13G, Beneficial Ownership, Eric Easom, Stock Options, Common Stock, SEC Filing